Home » Stocks » SRRK

Scholar Rock Holding Corporation (SRRK)

Stock Price: $31.25 USD -1.18 (-3.64%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 1.08B
Revenue (ttm) 15.08M
Net Income (ttm) -97.08M
Shares Out 36.38M
EPS (ttm) -2.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $31.25
Previous Close $32.43
Change ($) -1.18
Change (%) -3.64%
Day's Open 32.12
Day's Range 30.70 - 33.43
Day's Volume 257,666
52-Week Range 11.33 - 70.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a presentation of results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 SMA at EAN

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by Dr. Thomas Crawford at the Cure SMA Annual SMA Conference.

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock receives fast track designation from the FDA for Apitegromab for the treatment of patients with spinal muscular atrophy.

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a trials in progress poster presentation at the 2021 ASCO Annual Meeting, being held from June 4-8, 2021.

2 months ago - Business Wire

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -10.14% and -29.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for ...

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that findings from its Phase 1 trial of apitemograb were published in the peer-reviewed journal Advances in Therapy.

2 months ago - Business Wire

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,981,981 with an expiry of May 2034.

3 months ago - Business Wire

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK)....

3 months ago - Newsfile Corp

These drugmaker stocks may have been hammered down to bargain-bin prices.

Other stocks mentioned: FREQ, SLDB
3 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 from April 10 - 15.

3 months ago - Business Wire

Scholar Rock (NASDAQ: SRRK) shares dropped despite the company reporting positive 12-month data on spinal muscular atrophy (SMA) candidate apitegromab. The 12-month update was broadly in line with the s...

3 months ago - Benzinga

Scholar Rock (NASDAQ: SRRK) has announced top-line data from the TOPAZ Phase 2 trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). In Cohort 1 (poole...

3 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental ...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the publication of preclinical development data for SRK-181 in the peer-reviewed journal International Journal of Toxicology.

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced issuance of U.S. patent protecting add-on or combination therapy with a myostatin inhibitor for spinal muscular atrophy (SMA).

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced its oral and poster presentations at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

4 months ago - Business Wire

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -27.42% and -53.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead f...

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

4 months ago - Business Wire

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

8 months ago - Business Wire

Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.

Other stocks mentioned: REPL
8 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factor...

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factor...

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factor...

9 months ago - Business Wire

Investors are fired up about the company's interim phase 2 results for an experimental spinal muscular atrophy drug.

9 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

9 months ago - Business Wire

Scholar Rock Holding Corp. (SRRK) CEO Tony Kingsley on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -22.64% and -40.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...

11 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

11 months ago - Business Wire

CAMBRIDGE, Mass--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental ...

11 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

11 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

1 year ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

1 year ago - Business Wire

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -480.00% and -74.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for...

1 year ago - Zacks Investment Research

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Scholar Rock has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Is (SRRK) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 31.58% and 38.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for...

1 year ago - Zacks Investment Research

About SRRK

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor ther... [Read more...]

Industry
Biotechnology
IPO Date
May 24, 2018
CEO
Nagesh Mahanthappa
Employees
119
Stock Exchange
NASDAQ
Ticker Symbol
SRRK
Full Company Profile

Financial Performance

In 2020, SRRK's revenue was $15.40 million, a decrease of -24.83% compared to the previous year's $20.49 million. Losses were -$86.48 million, 69.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is 64.67, which is an increase of 106.94% from the latest price.

Price Target
$64.67
(106.94% upside)
Analyst Consensus: Buy